FDA Approves Frunevetmab Injection for Treating Pain In Cats Associated with Asteoarthritis

With the U.S. Food and Drug Administration approval for Solensia (Frunevetmab injection) for treating pain in cats associated with asteoarthritis, the novel treatment has become the first of kind treatment. Also, the novel treatment has become the first monoclonal antibody (mAb) new animal drug to receive approval from FDA for use in any animal species.

Frunevetmab is the active ingredient in Solensia. Solensia is a type of protein will recognize protein and attach to the protein called nerve growth factor that will further help in regulating the pain. The Frunevetmab is the key ingredient as it attaches to the protein and helps the pain signal reaching to the brain.

Currently there are very limited options to treat the pain in cats associated with asteoarthritis. Advancements in veterinary medicine have led to the development of treatments instrumental in extending lives of cats and other animals. But, with longer lives comes the risk of chronic diseases like asteoarthritis.

This novel treatment becomes the first medicine to treat asteoarthritis related pain in cats providing relief to cats suffering from the chronic condition and improving their quality of life. With the first treatment and approval from FDA, the FDA’s Center for Veterinary Medicine hopes carry out research  and development to bring more such monoclonal antibody products with to treat chronic diseases in animals. Solensia will be available to the cat owners only by prescription from a licensed veterinarian.